N/A
Completed N=419
A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Hypertension
Source: ClinicalTrials.gov NCT01589510 ↗
Enrolled (actual)
419
Serious AEs
0.0%
Results posted
Jun 2014
Primary outcomePrimary: Intraocular Pressure (IOP) at Baseline — 21.23; 21.38 Millimeters of Mercury (mmHg)
Summary
A study of Lumigan® 0.01% as administered in standard practice for patients with POAG or OHT. All treatment decisions, care and diagnostic procedures provided are at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Intraocular Pressure (IOP) at Baseline |
21.23; 21.38 | — |
| PRIMARY IOP at Week 14 |
15.92; 16.05 | — |
| SECONDARY Physician Evaluation of IOP Lowering in the Study Eye(s) |
83; 233; 73; 6; 13; 28 | — |
| SECONDARY Patient Assessment of Tolerability on a 4-Point Scale |
201; 167; 16; 9 | — |
| SECONDARY Physician Assessment of Tolerability on a 4-Point Scale |
209; 171; 8; 4 | — |
| SECONDARY Percentage of Patients Who Discontinue Lumigan® 0.01% Prior to 14 Weeks of Treatment |
7.9 | — |
| SECONDARY Percentage of Patients Who Continue Lumigan® 0.01% Treatment |
86.2 | — |
| SECONDARY Physician Assessment of Patient Compliance Compared to Previous Therapy |
94; 88; 1; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of POAG or OHT
- Prescribed Lumigan® 0.01%
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT01589510). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.